Testing selinexor added to usual chemotherapy for glioblastoma that has come back
Original title: Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a safe dose and see if the drug helps.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether adding a drug called selinexor to the usual chemotherapy helps people whose brain tumor has returned.
Who this trial is for. This trial is for people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that has come back after earlier treatment. It tests selinexor given with the usual chemotherapy, temozolomide, and compares that pair against temozolomide by itself.
Where it stands. This trial has not reported results. It is looking at how safe selinexor is, what side effects it causes, and what dose works best. It is also measuring whether adding selinexor shrinks or steadies the tumor better than temozolomide alone. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: If your glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has come back, this is one more thing you can ask about. Your care team can tell you if it fits your situation. They can also explain what taking part would involve.
What it doesn't mean: This does not mean selinexor works. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.